Radiopharma CDMO & Supply Chain Report 2025
Capital has arrived in radiopharmaceuticals faster than the capability to manufacture at scale. This briefing maps where that gap sits: across isotope supply, high-containment facilities, decay-timed distribution, dual regulatory oversight and specialist talent, and it names the companies operating in each layer of the chain.
What this report answers
- Why has record investment in radioligand therapy not translated into manufacturing capacity?
- What makes a radiopharmaceutical CDMO structurally harder to build than a conventional one?
- Who actually operates in each layer of the radiopharma value chain, from isotope production to last-mile delivery?
- Which constraint binds first: isotope supply, shielded infrastructure, or specialist people?
- What did the Pluvicto supply interruption change about how the industry builds capacity?
- How are isotope producers, distributors and drug developers converging on the same full-stack model?
5-10
new radiochemistry PhDs granted annually in the United States, the briefing's estimate of the educational pipeline feeding the discipline that governs whether a radiopharmaceutical facility can be staffed.
$42bn
the upper end of the external market forecasts the briefing cites for radiopharmaceuticals by 2032 - a projection it treats as conditional on the supply constraints it goes on to examine.
What the analysis establishes
The gap between capital and capability
The briefing sets out the market forces that pulled Big Pharma into radioligand therapy over 2023 to 2025, then measures those commitments against the GMP capacity available to service them. It establishes why the imbalance is structural rather than cyclical, and why the same conditions that create the shortage also create the moat around anyone who solves it.
Five operational barriers that define the moat
A chapter-length deconstruction of what makes radiopharmaceutical manufacturing distinct: isotope supply fragility, the engineering conflict inside a facility that must be both sterile and radiologically contained, decay-timed logistics, oversight from both drug and nuclear regulators, and the human capital deficit. Each is examined for where it binds and why it resists rapid scaling.
A market map of the value chain
The longest chapter divides the ecosystem into six segments, from isotope supply and radiochemistry development through GMP manufacturing, preclinical and imaging CROs, cold chain logistics and enabling equipment. Each segment carries representative operators with their technology, geography and position described. A closing chapter tracks the companies that span more than one segment.
The pivot toward vertical integration
Profiles of five transformation routes into full-stack CDMO status: the isotope producer moving downstream, the distributor rolling up manufacturing, the hybrid developer acquired for its capability, the organic grower, and the purpose-built pure play. The briefing establishes what each route costs and what capability it actually buys.
Two case studies in supply chain failure and control
The Pluvicto supply interruption is treated as the formative event for the sector, with the response it triggered traced through to the network being built now. A second case examines an acquisition-led route to controlling the chain end to end. Both are used to test what redundancy is worth.
Where the strategic pressure lands next
The closing chapter frames the build-versus-buy decision, identifies the competitive archetypes now emerging, and sets out separate recommendations for drug developers and for investors. It states a view on which capability the industry will end up paying most for, and what that implies for consolidation.
How it was built
Compiled entirely from publicly available data and third-party sources; the briefing states plainly that no proprietary or non-public information was used. Market sizing is presented as a range drawn from multiple external forecasts rather than a single number, with the spread shown. The market map is explicitly representative rather than exhaustive, and companies are placed by their stated capability and disclosed transactions. Where the analysis moves from observed fact to ProGen Search's reading of the landscape, it says so.
Written for radiopharma CDMO and biotech leadership, private equity and venture investors underwriting the sector, and pharma teams selecting manufacturing partners for radioligand programmes.
Contents
- Executive Summary: A Market at a Critical Inflection Point
- The New Competitive Battleground: Market Dynamics Driving the CDMO Imperative
- Deconstructing the Moat: The Core Complexities of Radiopharma Operations
- The Radiopharmaceutical Value Chain: A Market Map of Key Players
- The Rise of the Vertically Integrated Player
- Strategic Outlook and Recommendations
- Footnotes on Cross-Segment Players
Organisations covered
Novartis, Telix Pharmaceuticals, Lantheus, Curium Pharma, Eckert & Ziegler, ITM Isotope Technologies Munich, NorthStar Medical Radioisotopes, BWXT Medical, SHINE Technologies, Niowave, TerraPower Isotopes, Ionetix, ASP Isotopes, SCK CEN, Nucleus RadioPharma, SpectronRx, AtomVie Global Radiopharma, PharmaLogic, Evergreen Theragnostics, SOFIE Biosciences, Orano Med, Perspective Therapeutics, Cardinal Health, Jubilant Radiopharma, IBA
The full 16-page briefing is free. Tell us where to send it and it downloads immediately.
The State of Radiopharmaceuticals 2026
This briefing maps the 2025 supply chain. The flagship report takes the sector a year further, with named capacity, current pipeline positions and the economics behind them.
See the full report →